PEER-REVIEWED Publications 2013

1 An internationally generalizable risk index for mortality after one year of antiretroviral therapy. JP Tate, AC Justice, MD Hughes, F Bonnet, P Reiss, A Mocroft, J Nattermann, FC Lampe, HC Bucher, TR Sterling, HM Crane, MM Kitahata, M May, J Sterne. 
AIDS. 2013 Feb 20;27(4):563-572. Epub ahead of print Nov 6 2012.abstract 

2 Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). 
J Infect Dis. 2013 Mar;207(5):759-67. abstract

3 Severe bacterial non-AIDS infections in HIV-positive persons: incidence rates and risk factors. OS Søgaard, J Reekie, M Ristola, D Jevtovic, I Karpov, M Beniowski, S Servitskiy, P Domingo, P Reiss, A Mocroft, O Kirk for EuroSIDA in EuroCoord. 

J Infect. 2013 Jan 24. abstract

4 Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AD Monforte, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, MG Law, R Weber, O Kirk, C Pradier, AN Phillips, JD Lundgren, CA Sabin.
AIDS. 2013 Jan 28;27(3):407-15. abstract

5 Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. DN Podlekareva, D Grint, FA Post, A Mocroft, AM Panteleev, RF Miller, JM Miro, M Bruyand, H Furrer,V Riekstina, E Girardi, MH Losso, JA Caylá, EA Malashenkov, N Obel, AM Skrahina, JD Lundgren, O Kirk; HIV-TB Study Group.
Int J Tuberc Lung Dis. 2013 Feb;17(2):198-206. abstract

6 Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study). FZ Dawood, F Khan, MP Roediger, ZM Zhang, A Swaminathan, H Klinker, J Hoy, JD Lundgren, JD Neaton, EZ Soliman; INSIGHT SMART Study Group. 
Am J Cardiol. 2013 Jan 1;111(1):118-24. Epub 2012 Oct 9. abstract 

7 Platelet count kinetics following interruption of antiretroviral treatment.  E Zetterberg, J Neuhaus, JV Baker, C Somboonwit, JM Llibre, A Palfreeman, M Chini, JD Lundgren; INSIGHT SMART Study Group. 
AIDS. 2013 Jan 2;27(1):59-68. abstract

8 Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. D Grint, L Peters, J Reekie, V Soriano, O Kirk, B Knysz, O Suetnov, A Lazzarin, B Ledergerber, J Rockstroh, A Mocroft A; EuroSIDA in EuroCoord.  
HIV Med. 2013 Mar 27. abstract

9 Association Between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. L Ryom, A Mocroft, O Kirk, SW Worm, DA Kamara, P Reiss, M Ross, CA Fux, P Morlat, O Moranne, C Smith, JD Lundgren; on behalf of the D:A:D study group. 
J Infect Dis. 2013 May;207(9):1359-1369. abstract

10 Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. AG Babiker, S Emery, G Fätkenheuer, FM Gordin, B Grund, JD Lundgren, JD Neaton, SL Pett, A Phillips, G Touloumi, MJ Vjecha.  
Clin. Trials. 2013;10(1 Suppl):S5-S36. abstract

11 Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients. L Peters, A Mocroft, V Soriano, J Rockstroh, A. Rauch, A Karlsson, B Knysz, C Pradier, K Zilmer, JD Lundgren, for EuroSIDA in EuroCoord.
PLoS One. PloS One. 2013 May 27;8(5):e64283. doi: 10.1371/journal.pone.0064283. abstract

12 When to start antiretroviral therapy: the need for an evidence base during early HIV infection. JD Lundgren, AG Babiker, FM Gordin, AH Borges, JD Neaton. 
BMC Med. 2013 Jun 14;11:148. doi: 10.1186/1741-7015-11-148. abstract

13 Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AH Borges, MJ Silverberg, D Wentworth, AE Grulich, G Fätkenheuer, R Mitsuyasu, G Tambussi, CA Sabin, J Neaton, JD Lundgren; for the INSIGHT SMART, ESPRIT, SILCAAT Study groups.
AIDS. 27(9(:1433-1441, June 1, 2013. abstract

14 Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D: A: D Study. CA Sabin, L Ryom, H Kovari, O Kirk, S de Wit, M Law, P Reiss, F Dabis, C Pradier, W El Sadr, AD Monforte, D Kamara, AN Phillips, JD Lundgren JD.
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):456-63. abstract

15 Advanced Chronic Kidney Disease (CKD), End-Stage Renal Disease (ESRD) and Renal Death among HIV-positive individuals in Europe. L Ryom, O Kirk, J Lundgren, P Reiss, C Pedersen, S De Wit, S Buzunova, J Gasiorowski, JM Gatell and A Mocroft on behalf of EuroSIDA in EuroCoord. 
HIV Medicine. 2013 Sep;14(8):503-8. abstract

16 Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). A Mocroft, JD Lundgren, M Sabin, A d'Arminio Monforte, N Brockmeyer, J Casabona, A Castagna, D Costagliola, F Dabis, S De Wit, G Fätkenheuer, H Furrer, AM Johnson, O Kirk, for the Late Presenters Working Group, on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. 
PLoS Med. 2013 10(9): e1001510. abstract

17 World Hepatitis Day 2013: Know it, Confront it. JV Lazarus, C Gore, T Nguyen, K Safreed-Harmon, I Sperle, RJJ Peck, H Harmanci, S Wiktor.
Lancet Global Health. 2013 Sept. Vol 1, Issue 3; e127-128. full text

18 Unnecessary injecting of medicines: a global challenge. C Gore, JV Lazarus, I Sperle, K Safreed-Harmon. 
Trop Med & Int'l Health. 2013 Sept. Vol 18, Issue 9;1157-1159. article

19 Primary health care providers' views on improving sexual and reproductive health care for adolescents in Bolivia, Ecuador, and Nicaragua. L Jaruseviciene, JV Lazarus, P Decat, AC Gorter et al. 
Global Health Action. 2013;6:10.3402/gha.v6i0.20444. abstract

20 Enabling factors for prescribing antibiotics for upper respiratory tract infections: the perspectives of Lithuanian and Russian general practitioners. L Jaruseviciene, R Radzeviciene-Jurgute, JV Lazarus, A Jurgutis, G Jarusevicius, L Bjerrum. 
Uppsala Journal of Medical Sciences. 2013 May;118(2):98-104. abstract

21 Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. SW Worm, M Bower, P Reiss, F Bonnet, M Law, G Fätkenheuer, A d'Arminio Monforte, DI Abrams, A Grulich, E Fontas, O Kirk, H Furrer, S De Wit, A Phillips, JD Lundgren, CA Sabin.
BMC Infect Dis. 2013 Oct 9;13(1):471. PMID:24106926. abstract

22 Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. D Grint, L Peters, C Schwarze-Zander, M Beniowski, C Pradier, M Battegay, D Jevtovic, V Soriano, JD Lundgren, JK Rockstroh, O Kirk and A Mocroft for EuroSIDA in EuroCoord.
HIV Medicine. 2013 Nov;14(10):614-23. abstract

23 Associations between immune depression and cardiovascular events in HIV infection. CA Sabin, L Ryom, S De Wit, A Mocroft, AN Phillips, SW Worm, R Weber, AD Monforte, P Reiss, D Kamara, W El-Sadr, C Pradier, F Dabis, M Law, J Lundgren. 
AIDS. 2013 Nov 13;27(17):2735-48. abstract

24 Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. V Cambino, S Bertagnolio, MR Jordan, JD Lundgren, A Phillips. 
J Infect Dis. 2013 Jun 15;207 Suppl 2:S57-62. abstract

25 The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. ME Johansen, J-U Jensen, MH Bestle, L Hein, AØ Lauritsen, H Tousi, KM Larsen, J Løken, T Mohr, K Thormar, PI Johansson, A Cozzi-Lepri, JD Lundgren.
PLoS One. 2013 Nov 28;8(11):e81477. abstract

26 TB Meningitis in HIV-positive patients in Europe and Argentina - Clinical outcome and factors associated with mortality. AM Werlinrud Efsen, A Panteleev, D Grint, DN Podlekareva, A Vassilenko, A Rakhmanova, I Zeltina, MH Losso, R Miller, E Girardi, J Caylá, F Post, JM Miro, M Bruyand, H Furrer, N Obel, JD Lundgren, A Mocroft, O Kirk, and the HIV/TB study group.
BioMed Research International. Sept 2013. abstract

27 Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. H Kovari, CA Sabin, B Ledergerber, L Ryom, SW Worm, C Smith, A Phillips, P Reiss, E Fontas, K Petoumenos, S De Wit, P Morlat, JD Lundgren, R Weber. 
Clin Infect Dis. 2013 Mar;56(6):870-9. abstract

28 Biomarker-guided clinical decisions: for patients, health economists or neither? JU Jensen. Eur Resp J. 2013 Oct;42(4):895-7. abstract

29 The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.
C da Cunha-Bang, N Kirkby, M Sønderholm, SS Sørensen, H Sengeløv, M Iversen, A Rasmussen, F Gustafsson, CM Frederiksen, J Kjaer, AC Lepri, JD Lundgren. 
Am J Transplant. 2013 Feb;13(2):458-66. abstract

30 The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. RT Jr Davey, R Lynfield, DE Dwyer, MH Losso, A Cozzi-Lepri, D Wentworth, HC Lane, R Dewar, A Rupert, JA Metcalf, SL Pett, TM Uyeki, JM Bruguera, B Angus, N Cummins, J Lundgren, JD Neaton; INSIGHT FLU 002 & 003 Study Groups. 
PLoS One. 2013;8(2):e57121. Epub 2013 Feb 27. abstract

31 Encephalitis in primary HIV infection: challenges in diagnosis and treatment. M Helleberg M, O Kirk. 
Int J STD AIDS. 2013 Jun;24(6):489-93. Epub 2013 Jul 9. abstract

32 The case for indicator condition-guided HIV screening. JV Lazarus, M Hoekstra, D Raben, V Delpech, T Coenen, JD Lundgren; HIV in Europe Initiative Steering Committee. 
HIV Med. 2013 Aug;14(7):445-8. Epub 2013 Mar 10. abstract

33 Editorial commentary: universal antiretroviral therapy for HIV infection? JD Lundgren, R Wood. 
Clin Infect Dis. 2013 Sep;57(6):888-90. Epub 2013 Jun 11. abstract

34 CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. A Mocroft, AN Phillips, J Gatell, A Horban, B Ledergerber, K Zilmer, D Jevtovic, F Maltez, D Podlekareva, JD Lundgren; EuroSIDA study in EuroCOORD. 
AIDS. 2013 Mar 27;27(6):907-18. abstract

35 The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. A Mocroft, HJ Furrer, JM Miro, P Reiss, C Mussini, O Kirk, S Abgrall, S Ayayi, B Bartmeyer, D Braun, A Castagna, A d'Arminio Monforte, B Gazzard, F Gutierrez, I Hurtado, K Jansen, L Meyer, P Muñoz, N Obel, P Soler-Palacin, A Papadopoulos, F Raffi, JT Ramos, JK Rockstroh, D Salmon, C Torti, J Warszawski, S de Wit, R Zangerle, C Fabre-Colin, J Kjaer, G Chene, J Grarup, JD Lundgren; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. 
Clin Infect Dis. 2013 Oct;57(7):1038-47. Epub 2013 Aug 6. abstract

36 Conclusions from the HIV in Europe Copenhagen 2012 Conference and ways forward: working together for optimal HIV testing and earlier care. D Raben, V Delpech, J de Wit, A Sullivan, JV Lazarus, N Dedes, T Coenen, J Lundgren; HIV in Europe Steering Committee. 
HIV Med. 2013 Oct;14 Suppl 3:1-5. abstract

37 Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? JK Rockstroh, L Peters, D Grint, V Soriano, P Reiss, Ad Monforte, M Beniowski, MH Losso, O Kirk, B Kupfer, A Mocroft; EuroSIDA in EuroCoord. 
J Hepatol. 2013 Aug;59(2):213-20. abstract

38 Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. AJ Rodger, T Bruun, P Vernazza, S Collins, V Estrada, J Van Lunzen, GM Corbelli, AN Phillips, JD Lundgren; PARTNER Study Group. 
Antivir Ther. 2013;18(3):285-7.  abstract

39 Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). AK Sullivan, D Raben, J Reekie, M Rayment, A Mocroft, S Esser, A Leon, J Begovac, K Brinkman, R Zangerle, A Grzeszczuk, A Vassilenko, V Hadziosmanovic, M Krasnov, A Sönnerborg, N Clumeck, J Gatell, B Gazzard, Ad Monforte, J Rockstroh, JD Lundgren. 
PLoS One. 2013;8(1):e52845.  abstract

40 The need for evidence-based use of antiretroviral therapy. Jens D Lundgren, Abdel G Babiker, Fred M Gordin, Álvaro H Borges and James D Neaton.
BMC Medicine, 2013 Jun 14;11:148. doi: 10.1186/1741-7015-11-148. (Article)

41 Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, JA Hontelez, S Humair, CC Kerr, DJ Klein, S Mishra, KM Mitchell, BE Nichols, P Vickerman, R Bakker et al.
Lancet Glob Health, 2013 Dec 10;2(1):23-34. abstract